. Increasingly, however, experts are intent on slowing or halting the disease process, before it has ravaged patients' brains. A lot of data is being generated on changes in imaging biomarkers before patients really become clinically significantly impaired. For example, there has been a lot of great work done in identifying patients early based on these biomarkers. The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease. Currently, medical biotechnology has brought new hopes in the treatment of Alzheimer's disease. For example one of the ongoing trials is related to bapineuzumab. Bapineuzumab is a monoclonal antibody (mAb) to target and clear ß-amyloid. This vaccine is the first new drug aimed at slowing or even halting AD progression.
